Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
$38.83
$0.01(0.04%)
At close: 4:00 PM EST
$38.83
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$13.30 - $40.62
Previous CloseN/A
Volume37.78K
Average Volume (3M)1.33M
Market Cap
$2.32B
Enterprise Value$2.22B
Total Cash (Recent Filing)$462.62M
Total Debt (Recent Filing)$399.00K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 20, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding59,800,407
10 Day Avg. Volume2,004,261
30 Day Avg. Volume1,328,069
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-48.34K
Enterprise Value/Ebitda-19.43
Forecast
1Y Price Target
$47.60Price Target Upside22.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.1
Revenue Forecast (FY)$10.00K
Bulls Say, Bears Say
Bulls Say
Acquisition InterestMerck's acquisition of a differentiated CML asset validates the therapeutic approach and increases strategic takeover interest in Enliven, potentially enhancing the company's valuation.
Clinical Responses In Refractory PatientsELVN-001 produced meaningful and durable molecular responses in heavily pretreated chronic myeloid leukemia patients, supporting potential benefit in second-line and later therapy settings.
Safety Profile And Dose FlexibilityA consistent safety profile across tested doses and absence of a clear dose-response suggest flexibility to choose an effective, tolerable dose for pivotal trials.
Bears Say
Competitive Benchmark PressureA competing BCR‑ABL inhibitor reported higher early response rates, establishing a competitive benchmark that could tighten ELVN-001's market positioning.
Data Immaturity And EvaluabilityEarly-stage response rates remain uncertain because many patients are not yet evaluable and immature analyses can bias results upward, creating uncertainty about definitive efficacy.
Financing And Cash Runway RiskLimited cash relative to burn increases the likelihood of future fundraising or partnership needs, which could dilute shareholders or constrain independent development options.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $40.62 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $2.32B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 44 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 03, 2026. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.095.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.46.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 59,800,407 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went up 4.278%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.60 (22.59% Upside)
$47.60 (22.59% Upside)
Blogger Sentiment
Neutral
ELVN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $295.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 27.9%
Last 30 Days ▲ 27.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.51%
12-Months-Change
Fundamentals
Return on Equity
-24.22%
Trailing 12-Months
Asset Growth
46.20%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$47.60
▲(22.59% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―